Fundraising FoxNeuroxt
7 known investors
Find your way into Neuroxt
Sign up to see every warm intro you have to Neuroxt
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Neuroxt team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
NeuroXT develops MRI-based AI software that predicts amyloid and tau burden to guide Alzheimer's disease treatment decisions.
Also known as NeuroXT · NeuroXT Inc.
Investors · 7
How we know: DAYLI Partners's portfolio page · Not right? Tell us
How we know: the VCSheet dataset · research · neuroxt.com · Not right? Tell us
Also in the syndicate · 3
Company profile
researched Aug 2026NeuroXT Inc. is a Korean medical imaging AI company that builds software for the diagnosis and treatment management of neurodegenerative disease, with a focus on Alzheimer's disease. Its core approach applies AI models to brain MRI scans in order to estimate amyloid and tau burden, biomarkers conventionally measured with PET imaging. The company positions this as a way to perform biomarker-based assessment and predict treatment suitability using MRI alone, avoiding the cost of PET scans.
The product line includes NEXT-Cue, an AI solution that analyzes brain MRI together with clinical information to support assessment of cognitive decline in patients at risk of Alzheimer's disease; NEXT-STAGE, which infers regional tau burden from routine MRI and is described as complementary to PET and aimed at research teams in biopharmaceutical companies and academic hospitals; and a multimodal platform that measures in-vivo synaptic integrity to assess the effect of synapse-targeted therapies.
Founding story
NeuroXT Inc. was founded in April 2022. In June 2022 it secured a technology transfer agreement covering six key patents from Korea University's Samrak Cooperation Center and raised seed investment.
Business model
NeuroXT supplies AI imaging software to hospitals and to research groups in biopharma and academic medicine, positioning its products as a lower-cost alternative or complement to PET-based biomarker assessment.
Traction
Between 2022 and 2023 the company completed seed and Pre-A Series financings, obtained venture company certification and TIPS selection, established a corporate R&D center, and entered a global clinical collaboration with Newcle Science Inc.
▸Full profile — market position, technology, go-to-market, history
Market position
NeuroXT operates in AI-based neuroimaging for Alzheimer's disease, describing itself as addressing the gap between newly available Alzheimer's therapies and the limited share of patients who benefit from them.
The company's stated approach derives amyloid and tau biomarker information from MRI alone, removing the need for costly PET scans, and identifies the therapeutic window at which a patient is most likely to benefit from treatment.
Technology
AI models applied to brain MRI scans, combined with clinical information, to predict amyloid and tau burden, infer regional tau distribution, assess cognitive decline, and measure in-vivo synaptic integrity in a multimodal platform.
Go-to-market
The company markets its platform to hospitals worldwide and to biopharma and academic research teams, and works through partnerships with investors, universities and industry collaborators including AJU IB Investment, DAYLI Partners, Kakao Ventures, Korea Investment Accelerator, Korea University Research and Business Foundation, LULULAB, Mirae Ventures and Smilegate Investment.
Hospitals and clinicians treating patients at risk of Alzheimer's disease, and research teams at biopharmaceutical companies and academic hospitals.
History
Founded in April 2022, NeuroXT raised seed investment from AJU IB and Mirae Ventures in June 2022 and secured a technology transfer agreement for six patents from Korea University. In July 2022 it established a corporate R&D center, was certified as a venture company, and was selected for TIPS (Tech Incubator Program for Startup Korea). In August 2022 it signed a global clinical collaboration with Newcle Science Inc. Pre-A Series investment followed from Kakao Ventures in December 2022, Daily Partners in April 2023, and Smilegate and Korea Investment Accelerator in May 2023, when it was also selected for the Early Startup Package.
Compiled by commissioned research from 2 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Timeline · 10
launches, deals, and filingsNEXT-Cue analyzes brain MRI with clinical information to support assessment of cognitive decline; NEXT-STAGE infers regional tau burden from routine MRI.
Selected for the Tech Incubator Program for Startup Korea (TIPS).
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
▸Research sources · 2
primary sources listed
- About Usneuroxt.com · web
2 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Neuroxt do?
- NeuroXT develops MRI-based AI software that predicts amyloid and tau burden to guide Alzheimer's disease treatment decisions.
- Who are Neuroxt's investors?
- Neuroxt's investors include DAYLI Partners, Kakao Ventures, Aju IB Investment, Smilegate Investment.